IRIS
MILANI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.559
AS - Asia 3.190
EU - Europa 2.340
SA - Sud America 486
AF - Africa 185
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.768
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.429
CN - Cina 1.098
SG - Singapore 850
IE - Irlanda 665
HK - Hong Kong 432
VN - Vietnam 368
BR - Brasile 354
RU - Federazione Russa 326
DE - Germania 267
IT - Italia 261
FI - Finlandia 215
FR - Francia 165
ZA - Sudafrica 129
GB - Regno Unito 109
IN - India 104
BD - Bangladesh 83
CA - Canada 72
SE - Svezia 64
UA - Ucraina 60
JP - Giappone 38
AR - Argentina 37
MX - Messico 36
PL - Polonia 36
ES - Italia 32
IQ - Iraq 30
NL - Olanda 26
TR - Turchia 26
AT - Austria 24
CO - Colombia 24
PK - Pakistan 22
ID - Indonesia 19
SA - Arabia Saudita 17
CL - Cile 15
EC - Ecuador 15
VE - Venezuela 15
MA - Marocco 13
AL - Albania 12
LT - Lituania 12
PH - Filippine 12
BE - Belgio 10
EG - Egitto 10
GR - Grecia 9
UZ - Uzbekistan 9
IR - Iran 8
MY - Malesia 8
PY - Paraguay 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
AU - Australia 6
AZ - Azerbaigian 6
BO - Bolivia 6
DK - Danimarca 6
PT - Portogallo 6
BG - Bulgaria 5
ET - Etiopia 5
KZ - Kazakistan 5
PE - Perù 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
LV - Lettonia 4
MU - Mauritius 4
TH - Thailandia 4
AM - Armenia 3
IL - Israele 3
KH - Cambogia 3
KR - Corea 3
LB - Libano 3
RO - Romania 3
BB - Barbados 2
BS - Bahamas 2
CR - Costa Rica 2
EU - Europa 2
HR - Croazia 2
KW - Kuwait 2
LU - Lussemburgo 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SY - Repubblica araba siriana 2
VG - Isole Vergini Britanniche 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
Totale 10.749
Salva come PNG Salva come JPEG
Città #
Dublin 665
San Jose 548
Chandler 522
Ashburn 460
Singapore 452
Hong Kong 419
Dallas 384
Beijing 276
Boardman 174
Los Angeles 146
Nanjing 143
Ho Chi Minh City 133
Helsinki 131
Lauterbourg 124
Johannesburg 121
Jacksonville 106
Council Bluffs 103
Princeton 98
Lawrence 93
Hanoi 90
New York 90
Medford 84
Munich 84
Wilmington 71
Pavia 65
Nanchang 59
Buffalo 54
Redondo Beach 54
Shanghai 53
Moscow 43
Milan 40
Shenyang 39
Hebei 38
São Paulo 37
Santa Clara 36
Changsha 35
Ann Arbor 34
Tokyo 34
Orem 33
Jiaxing 32
Montreal 32
Piscataway 32
Turku 32
Tianjin 28
Warsaw 28
Chicago 27
Frankfurt am Main 27
Chennai 26
Norwalk 26
Nuremberg 26
Denver 25
London 24
Da Nang 23
Hangzhou 21
Houston 21
Haiphong 19
Seattle 19
Stockholm 19
San Francisco 18
Atlanta 17
Falkenstein 17
Toronto 17
Mexico City 16
Guangzhou 15
Poplar 15
Woodbridge 15
Pune 14
The Dalles 14
Washington 14
Manchester 13
Rio de Janeiro 13
Amsterdam 12
Ankara 12
Brooklyn 12
Baghdad 11
Boston 11
Induno Olona 11
Rome 11
Tirana 11
Vienna 11
Brussels 10
Phoenix 10
Brasília 9
Fairfield 9
Hyderabad 9
Zhengzhou 9
Biên Hòa 8
Cairo 8
Charlotte 8
Medellín 8
Querétaro 8
Turin 8
Athens 7
Dhaka 7
Düsseldorf 7
Marseille 7
Paris 7
Redwood City 7
Tamm 7
Tashkent 7
Totale 7.118
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 184
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 153
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 136
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 133
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 131
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 129
A patient with AL amyloidosis with negative free light chain results 128
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 124
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 123
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 123
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 121
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 120
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 120
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 117
A practical approach to the diagnosis of systemic amyloidoses 116
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 112
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 111
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 110
Prognostication of survival and progression to dialysis in AA amyloidosis 110
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 108
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 108
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 108
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 108
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 107
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 106
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 106
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis 105
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 105
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 104
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 102
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 102
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 102
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 102
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 101
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 100
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 97
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy 94
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 93
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 92
A case of monoclonal gammopathy of renal significance 92
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 91
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 90
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 89
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 89
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 88
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 88
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 87
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 85
Development and Validation of Staging Systems for AA Amyloidosis 84
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 84
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 83
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 83
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 83
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 83
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 80
The lung in amyloidosis 79
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 78
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 76
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts 76
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 75
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 75
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 75
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 74
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions 74
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. 73
Attitudes about when and how to treat patients with AL amyloidosis: an international survey 72
Management of AL amyloidosis in 2020 72
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis 70
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 68
HeLLePhant: A phantom mimicking non-small cell lung cancer for texture analysis in CT images 67
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 67
The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns. 67
A powerful oral triplet for AL amyloidosis 67
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 67
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 66
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 65
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 64
Predicting survival in light chain amyloidosis 64
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance 63
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 62
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 61
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis 60
Monoclonal IgM-related AL amyloidosis 59
Conventional Therapy for Amyloid Light-Chain Amyloidosis 58
Management of AL amyloidosis in 2020 58
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma 55
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients 55
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 54
Totale 9.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022413 5 2 12 0 12 6 6 33 24 21 54 238
2022/20231.570 166 141 20 87 110 135 14 83 753 11 33 17
2023/2024678 81 139 32 51 61 135 17 37 6 25 49 45
2024/20251.899 49 123 32 49 22 159 131 90 473 94 234 443
2025/20265.242 341 330 464 651 760 213 896 282 507 358 185 255
2026/2027140 140 0 0 0 0 0 0 0 0 0 0 0
Totale 11.025